-market.png&w=256&q=75)
Adult Growth Hormone Deficiency Market Summary
- According to DelveInsight, Adult Growth Hormone Deficiency Market is expected to grow at a decent CAGR by 2032.
- Adult Growth Hormone Deficiency Companies are Ascendis Pharma, Genexine, OPKO Health and others.
Factors affecting Adult Growth Hormone Deficiency Market Growth
-
Rising Prevalence of Congenital Adrenal Hyperplasia (CAH)
Increased recognition and diagnosis of genetic endocrine disorders are driving market demand.
-
Advancements in Diagnostic Techniques
Newborn screening, genetic testing, and hormonal assays facilitate early and accurate diagnosis.
-
Growing Demand for Personalized Therapies
Individualized treatment approaches, including glucocorticoid therapy and enzyme replacement, support market growth.
-
Limited Effective Treatment Options
High unmet medical need for safe and efficacious therapies encourages development of novel drugs.
-
Increasing Awareness Among Healthcare Professionals and Patients
Education programs improve early diagnosis and adherence to treatment regimens.
-
Expansion of Healthcare Infrastructure
Better access to endocrinology specialists and pediatric care centers enhances treatment uptake.
-
Government and NGO Initiatives
Programs supporting genetic screening, rare disease management, and patient awareness drive diagnosis and therapy adoption.
-
Technological Advancements in Drug Delivery
Innovations such as sustained-release formulations and pediatric-friendly therapies improve patient compliance.
-
Strategic Collaborations & Clinical Research
Partnerships between pharmaceutical companies, research institutes, and hospitals accelerate drug development.
-
Growing Patient Advocacy and Support Programs
Rare disease organizations help raise awareness and facilitate access to treatment.
DelveInsight's "Adult Growth Hormone Deficiency (AGHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Adult Growth Hormone Deficiency (AGHD), historical and forecasted epidemiology as well as the Adult Growth Hormone Deficiency (AGHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Adult Growth Hormone Deficiency (AGHD) market report provides current treatment practices, emerging drugs, Adult Growth Hormone Deficiency (AGHD) market share of the individual therapies, current and forecasted Adult Growth Hormone Deficiency (AGHD) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Adult Growth Hormone Deficiency (AGHD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Adult Growth Hormone Deficiency (AGHD) market.
Scope of the Adult Growth Hormone Deficiency Market | |
|
Study Period |
2020-2034 |
|
Forecast Period |
2025-2034 |
|
Geographies Covered |
US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan |
|
Adult Growth Hormone Deficiency Epidemiology |
|
|
Adult Growth Hormone Deficiency Market |
|
|
Market Analysis |
|
|
Adult Growth Hormone Deficiency Market players |
|
|
Future opportunity |
Future opportunities in Adult Growth Hormone Deficiency lie in long-acting GH formulations, personalized dosing through biomarkers, improved diagnostic awareness, and expansion into emerging markets. Advances in delivery systems and real-world evidence can enhance adherence, outcomes, and market growth. |
Adult Growth Hormone Deficiency (AGHD) Disease Understanding
Adult Growth Hormone Deficiency (AGHD) is a rare endocrine disorder characterized by insufficient secretion of growth hormone in adulthood, often resulting from pituitary or hypothalamic dysfunction. It can develop during childhood and persist into adulthood or be acquired later due to tumors, surgery, radiation therapy, or traumatic brain injury. AGHD is associated with altered body composition, reduced bone density, impaired lipid metabolism, and diminished quality of life.
Adult Growth Hormone Deficiency (AGHD) Diagnosis
The diagnosis of AGHD is clinically challenging due to nonspecific symptoms such as fatigue, decreased muscle mass, increased adiposity, and mood disturbances. Biochemical confirmation is essential and typically involves growth hormone stimulation tests, including the insulin tolerance test (ITT), glucagon stimulation test, or macimorelin test. Low insulin-like growth factor-1 (IGF-1) levels support the diagnosis, particularly in patients with known pituitary disease.
Adult Growth Hormone Deficiency (AGHD) Treatment
Treatment of AGHD primarily involves growth hormone replacement therapy (GHRT) using recombinant human growth hormone. Therapy is individualized based on age, sex, and clinical response, with dose titration guided by IGF-1 levels. GHRT has been shown to improve body composition, bone mineral density, cardiovascular risk markers, and overall quality of life, with ongoing research focused on long-acting formulations to enhance adherence.
Adult Growth Hormone Deficiency (AGHD) Epidemiology
The Adult Growth Hormone Deficiency (AGHD) epidemiology section provides insights about the historical and current Adult Growth Hormone Deficiency (AGHD) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Adult Growth Hormone Deficiency (AGHD) market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings from Adult Growth Hormone Deficiency Epidemiological Analyses and Forecast
The disease epidemiology covered in the report provides historical as well as forecasted Adult Growth Hormone Deficiency (AGHD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
- According to DelveInsight's analysis, the diagnosed prevalence cases of GHD in US exceeds 70,000 in the year 2024 reflecting a significant burden within the affected population.
- Secondary data suggest that GHD affects approximately 1.8 to 2.9 out of every 10,000 children, indicating its rarity within pediatric populations. This low prevalence underscores the need for heightened clinical vigilance and diagnostic precision.
- Secondary analysis indicate that in US, AGHD impacts roughly 2 to 3 individuals per 10,000. It arises from diverse etiologies, including genetic alterations, developmental defects, traumatic brain injury, and tumors affecting the pituitary or hypothalamus, among other contributing factors.
Country Wise- Adult Growth Hormone Deficiency (AGHD) Epidemiology
The epidemiology segment also provides the Adult Growth Hormone Deficiency (AGHD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Adult Growth Hormone Deficiency (AGHD) Drug Analysis
The drug chapter segment of the Adult Growth Hormone Deficiency (AGHD) report encloses the detailed analysis of Adult Growth Hormone Deficiency (AGHD) marketed drugs and late-stage (Phase-III and Phase-II) Adult Growth Hormone Deficiency (AGHD) pipeline drugs. It also helps to understand the Adult Growth Hormone Deficiency (AGHD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Adult Growth Hormone Deficiency (AGHD) Marketed Drugs
The Adult Growth Hormone Deficiency market report provides the details of the marketed products/off-label treatments available for Adult Growth Hormone Deficiency (AGHD) treatment.
Adult Growth Hormone Deficiency (AGHD) Emerging Drugs
The Adult Growth Hormone Deficiency market report provides the details of the emerging therapies under the late and mid-stage of development for Adult Growth Hormone Deficiency (AGHD) treatment.
TransCon hGH (lonapegsomatropin): Ascendis Pharma
TransCon hGH, marketed as SKYTROFA (lonapegsomatropin-tcgd), is a once-weekly prodrug formulation of somatropin developed using a proprietary linker technology that allows sustained release of unmodified recombinant growth hormone. Approved in the US for pediatric GHD, it mimics the therapeutic profile of daily hGH injections.
- Currently, TransCon hGH has completed Phase III clinical trials to evaluate its efficacy and safety in AGHD.
- In December 2024, Ascendis Pharma confirmed that the US FDA had accepted its supplemental Biologics License Application (sBLA) for formal review, assigning a Prescription Drug User Fee Act (PDUFA) target decision date of July 27, 2025.
- In September 2024, Ascendis Pharma submitted a sBLA to the US FDA seeking to expand the approved indication for TransCon hGH, aiming to include treatment of AGHD.
GX-H9: Genexine
GX-H9 is a long-acting hGH therapy utilizing hyFc fusion protein technology to extend its half-life in the body. Designed for once-weekly or twice-monthly dosing, it offers a bio-better alternative to traditional daily hGH injections, greatly enhancing treatment convenience and potentially improving patient compliance and therapeutic outcomes.
- In 2016, the US granted Orphan Drug Designation (ODD) for a treatment targeting AGHD. This regulatory status acknowledges the rarity and medical need associated with AGHD, potentially facilitating development incentives such as market exclusivity, tax benefits, and streamlined approval pathways.
- In June 2012, Handok and Genexine entered into a strategic partnership through a technology transfer and joint development agreement focused on creating a long-acting growth hormone therapy. This collaboration aimed to advance innovative treatment solutions by leveraging both companies’ expertise in biopharmaceutical development and sustainability.
Adult Growth Hormone Deficiency (AGHD) Market Outlook
The Adult Growth Hormone Deficiency (AGHD) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Adult Growth Hormone Deficiency (AGHD) market trends by analyzing the impact of current Adult Growth Hormone Deficiency (AGHD) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Adult Growth Hormone Deficiency (AGHD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Adult Growth Hormone Deficiency (AGHD) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Adult Growth Hormone Deficiency (AGHD) market in 7MM is expected to witness a major change in the study period 2019-2032.
The treatment landscape for AGHD primarily involves rhGH replacement therapy, usually administered via daily subcutaneous injections. This therapy improves body composition, bone density, quality of life, and metabolic abnormalities. Due to burdensome daily dosing and poor adherence, long-acting GH formulations with less frequent dosing such as weekly injections are emerging. Treatment is individualized based on age, clinical response, IGF-1 levels, and side effects, with careful dose titration and monitoring recommended.
Recent innovations, notably the approval of SOGROYA (somapacitan), are reshaping the AGHD landscape. As a long-acting GH analog, SOGROYA enhances adherence through weekly dosing and delivers robust outcomes via direct GH receptor activation and IGF-1–mediated metabolic regulation. Additionally, the off-label use of recombinant GH therapies continues to sustain market momentum.
Key Findings from the Adult Growth Hormone Deficiency Market Forecast Report
This section includes a glimpse of the Adult Growth Hormone Deficiency (AGHD) market in 7MM.
The United States Adult Growth Hormone Deficiency Market Outlook
This section provides the total Adult Growth Hormone Deficiency (AGHD) market size and market size by therapies in the United States.
EU-5 Countries: Adult Growth Hormone Deficiency Market Outlook
The total Adult Growth Hormone Deficiency (AGHD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Adult Growth Hormone Deficiency Market Outlook
The total Adult Growth Hormone Deficiency (AGHD) market size and market size by therapies in Japan is also mentioned.
Adult Growth Hormone Deficiency (AGHD) Market Recent Developments and Breakthroughs
- In December 2024, Scendis Pharma A/S (Nasdaq: ASND) announced that the U.S. FDA has accepted for review its supplemental Biologics License Application (sBLA) for TransCon hGH (lonapegsomatropin-tcgd) in adult growth hormone deficiency (GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025.
Adult Growth Hormone Deficiency (AGHD) Drugs Uptake
This section focuses on the rate of uptake of the potential Adult Growth Hormone Deficiency (AGHD) drugs recently launched in the Adult Growth Hormone Deficiency (AGHD) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Adult Growth Hormone Deficiency (AGHD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Adult Growth Hormone Deficiency (AGHD) Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Adult Growth Hormone Deficiency (AGHD) market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Adult Growth Hormone Deficiency (AGHD) Clinical Trial Activities
The Adult Growth Hormone Deficiency (AGHD) market report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Adult Growth Hormone Deficiency (AGHD) Companies involved in developing targeted therapeutics.
Adult Growth Hormone Deficiency Pipeline Development Activities
The Adult Growth Hormone Deficiency (AGHD) Market report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Adult Growth Hormone Deficiency (AGHD) emerging therapies.
Adult Growth Hormone Deficiency Market Access and Reimbursement
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Latest KOL Views on Adult Growth Hormone Deficiency
To keep up with current Adult Growth Hormone Deficiency (AGHD) market trends, we take KOLs and SMEs ' opinion working in the Adult Growth Hormone Deficiency (AGHD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Adult Growth Hormone Deficiency (AGHD) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Adult Growth Hormone Deficiency Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Adult Growth Hormone Deficiency (AGHD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Adult Growth Hormone Deficiency Market Report
- The report covers the descriptive overview of Adult Growth Hormone Deficiency (AGHD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Adult Growth Hormone Deficiency (AGHD) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Adult Growth Hormone Deficiency (AGHD) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Adult Growth Hormone Deficiency (AGHD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adult Growth Hormone Deficiency (AGHD) market
Adult Growth Hormone Deficiency Market Report Highlights
- In the coming years, the Adult Growth Hormone Deficiency (AGHD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Adult Growth Hormone Deficiency (AGHD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Adult Growth Hormone Deficiency (AGHD). The launch of emerging therapies will significantly impact the Adult Growth Hormone Deficiency (AGHD) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Adult Growth Hormone Deficiency (AGHD)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Adult Growth Hormone Deficiency (AGHD) Market Report Insights
- Adult Growth Hormone Deficiency (AGHD) Patient Population
- Adult Growth Hormone Deficiency Therapeutic Approaches
- Adult Growth Hormone Deficiency (AGHD) Pipeline Analysis
- Adult Growth Hormone Deficiency (AGHD) Market Size
- Adult Growth Hormone Deficiency Market Trends
- Adult Growth Hormone Deficiency (AGHD) Market Opportunities
- Impact of upcoming Adult Growth Hormone Deficiency (AGHD) Therapies
Adult Growth Hormone Deficiency (AGHD) Market Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Adult Growth Hormone Deficiency (AGHD) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Adult Growth Hormone Deficiency Market
- Adult Growth Hormone Deficiency Drugs Uptake
Adult Growth Hormone Deficiency (AGHD) Market Report Assessment
- Current Treatment Practices
- Unmet Needs
- Adult Growth Hormone Deficiency (AGHD) Pipeline Product Profiles
- Adult Growth Hormone Deficiency (AGHD) Market Attractiveness
- Adult Growth Hormone Deficiency Market Drivers
- Adult Growth Hormone Deficiency Market Barriers
Key Questions Answered in the Adult Growth Hormone Deficiency Report
Adult Growth Hormone Deficiency Market Insights
- What was the Adult Growth Hormone Deficiency (AGHD) drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Adult Growth Hormone Deficiency (AGHD) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Adult Growth Hormone Deficiency (AGHD) market size during the forecast period (2019-2032)?
- At what CAGR, the Adult Growth Hormone Deficiency (AGHD) market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Adult Growth Hormone Deficiency (AGHD) market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Adult Growth Hormone Deficiency (AGHD) market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Adult Growth Hormone Deficiency Epidemiology Insights
- What are the disease risk, burden, and regional/ethnic differences of the Adult Growth Hormone Deficiency (AGHD)?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Adult Growth Hormone Deficiency (AGHD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Adult Growth Hormone Deficiency (AGHD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adult Growth Hormone Deficiency (AGHD)?
- Out of all 7MM countries, which country would have the highest prevalent population of Adult Growth Hormone Deficiency (AGHD) during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Adult Growth Hormone Deficiency (AGHD) treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Adult Growth Hormone Deficiency (AGHD) in the USA, Europe, and Japan?
- What are the Adult Growth Hormone Deficiency (AGHD) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Adult Growth Hormone Deficiency (AGHD)?
- How many therapies are in-development by each company for Adult Growth Hormone Deficiency (AGHD) treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Adult Growth Hormone Deficiency (AGHD) treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Adult Growth Hormone Deficiency (AGHD) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adult Growth Hormone Deficiency (AGHD) and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Adult Growth Hormone Deficiency (AGHD)?
- What are the global historical and forecasted market of Adult Growth Hormone Deficiency (AGHD)?
Reasons to buy the Adult Growth Hormone Deficiency Market Report
- The report will help in developing business strategies by understanding trends shaping and driving the Adult Growth Hormone Deficiency (AGHD) market
- To understand the future market competition in the Adult Growth Hormone Deficiency (AGHD) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Adult Growth Hormone Deficiency (AGHD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Adult Growth Hormone Deficiency (AGHD) market
- To understand the future market competition in the Adult Growth Hormone Deficiency (AGHD) market.
-pipeline.png&w=256&q=75)
